Pinnacle Wealth Planning Services Inc. Buys Shares of 15,388 Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Pinnacle Wealth Planning Services Inc. purchased a new stake in Fennec Pharmaceuticals Inc (NASDAQ:FENC) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,388 shares of the company’s stock, valued at approximately $97,000. Pinnacle Wealth Planning Services Inc. owned approximately 0.06% of Fennec Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Barclays PLC lifted its holdings in shares of Fennec Pharmaceuticals by 274.3% in the third quarter. Barclays PLC now owns 31,319 shares of the company’s stock valued at $157,000 after purchasing an additional 22,951 shares in the last quarter. State Street Corp raised its holdings in Fennec Pharmaceuticals by 2.2% during the third quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after acquiring an additional 7,053 shares in the last quarter. Franklin Resources Inc. boosted its position in Fennec Pharmaceuticals by 18.7% during the third quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after purchasing an additional 2,330 shares during the last quarter. Advantage Alpha Capital Partners LP acquired a new position in Fennec Pharmaceuticals during the third quarter valued at approximately $264,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Fennec Pharmaceuticals by 10.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company’s stock valued at $386,000 after purchasing an additional 5,694 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on FENC shares. Wedbush restated an “outperform” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Friday, December 20th. Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th. Finally, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Tuesday, December 17th.

Fennec Pharmaceuticals Stock Up 1.0 %

FENC opened at $6.88 on Friday. Fennec Pharmaceuticals Inc has a twelve month low of $3.96 and a twelve month high of $11.49. The company has a 50-day simple moving average of $6.39 and a 200 day simple moving average of $5.61. The stock has a market capitalization of $189.63 million, a price-to-earnings ratio of -68.79 and a beta of 0.36.

Insider Transactions at Fennec Pharmaceuticals

In other news, Director Rosty Raykov sold 10,000 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total value of $67,900.00. Following the completion of the transaction, the director now owns 68,725 shares of the company’s stock, valued at approximately $466,642.75. This represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 31,186 shares of company stock valued at $203,389. 10.98% of the stock is currently owned by insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.